Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use OPDUALAG safely and effectively. See full prescribing information for OPDUALAG. OPDUALAG™ (nivolumab and relatlimab-rmbw) injection, for intravenous useInitial U.S. Approval: 2022
Medication labelWhy this: Advisory · dailymed-prescription
OPDUALAG™ is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.
- generic_name
- nivolumab and relatlimab-rmbw
- product_names
- nivolumab and relatlimab-rmbw
- ndc
- 0003-7125, 0003-7125-11
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en